"YASMIN" en el pelo y...patente anulada.

European Patent Office decides on Yasmin® patent challenge

09/07/2011

The FINANCIAL -- Berlin, July 8, 2011 – The Board of Appeal of the European Patent Office has decided to revoke Bayer Pharma AG’s formulation patent for Yasmin®, Yasminelle® and YAZ® (EP 1214076 - micronization). This annuls the opposition division´s decision in 2006 confirming the respective patent against which Hexal (Sandoz) submitted a notice of appeal. A decision on possible next steps will be taken by the company after studying the reasons of the decision. “We are disappointed by the decision that the European Patent Office didn’t concur with our legal opinion”, said Dr. Flemming Ornskov, Head of Strategic Marketing General Medicine at Bayer HealthCare Pharmaceuticals. “In spite of the Board of Appeal´s decision we remain confident that we can maintain our European leadership position in Women’s Healthcare with innovative product launches. Our late-stage pipeline includes a new hormonal intrauterine contraceptive (LCS) and a contraceptive patch.”